No Cover Image

Journal article 650 views 650 downloads

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial / Christopher Sorli, Shin-ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Steve Bain

The Lancet Diabetes & Endocrinology, Volume: 5, Issue: 4, Pages: 251 - 260

Swansea University Author: Steve Bain

  • Sorli2017.pdf

    PDF | Accepted Manuscript

    Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND).

    Download (866.67KB)
Published in: The Lancet Diabetes & Endocrinology
ISSN: 2213-8587
Published: Elsevier BV 2017
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa31739
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2017-01-25T14:56:58Z
last_indexed 2020-07-31T18:48:34Z
id cronfa31739
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2020-07-31T14:43:35.4427937</datestamp><bib-version>v2</bib-version><id>31739</id><entry>2017-01-25</entry><title>Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2017-01-25</date><deptcode>BMS</deptcode><abstract/><type>Journal Article</type><journal>The Lancet Diabetes &amp; Endocrinology</journal><volume>5</volume><journalNumber>4</journalNumber><paginationStart>251</paginationStart><paginationEnd>260</paginationEnd><publisher>Elsevier BV</publisher><issnPrint>2213-8587</issnPrint><keywords/><publishedDay>1</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2017</publishedYear><publishedDate>2017-04-01</publishedDate><doi>10.1016/s2213-8587(17)30013-x</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2020-07-31T14:43:35.4427937</lastEdited><Created>2017-01-25T09:18:36.6795613</Created><path><level id="1">Swansea University Medical School</level><level id="2">Medicine</level></path><authors><author><firstname>Christopher</firstname><surname>Sorli</surname><order>1</order></author><author><firstname>Shin-ichi</firstname><surname>Harashima</surname><order>2</order></author><author><firstname>George M</firstname><surname>Tsoukas</surname><order>3</order></author><author><firstname>Jeffrey</firstname><surname>Unger</surname><order>4</order></author><author><firstname>Julie Derving</firstname><surname>Karsb&#xF8;l</surname><order>5</order></author><author><firstname>Thomas</firstname><surname>Hansen</surname><order>6</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>7</order></author></authors><documents><document><filename>0031739-25012017092302.pdf</filename><originalFilename>Sorli2017.pdf</originalFilename><uploaded>2017-01-25T09:23:02.6500000</uploaded><type>Output</type><contentLength>917546</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><action/><embargoDate>2017-07-17T00:00:00.0000000</embargoDate><documentNotes>Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807>
spelling 2020-07-31T14:43:35.4427937 v2 31739 2017-01-25 Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2017-01-25 BMS Journal Article The Lancet Diabetes & Endocrinology 5 4 251 260 Elsevier BV 2213-8587 1 4 2017 2017-04-01 10.1016/s2213-8587(17)30013-x COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2020-07-31T14:43:35.4427937 2017-01-25T09:18:36.6795613 Swansea University Medical School Medicine Christopher Sorli 1 Shin-ichi Harashima 2 George M Tsoukas 3 Jeffrey Unger 4 Julie Derving Karsbøl 5 Thomas Hansen 6 Steve Bain 0000-0001-8519-4964 7 0031739-25012017092302.pdf Sorli2017.pdf 2017-01-25T09:23:02.6500000 Output 917546 application/pdf Accepted Manuscript true 2017-07-17T00:00:00.0000000 Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND). true eng
title Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
spellingShingle Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Steve, Bain
title_short Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
title_full Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
title_fullStr Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
title_full_unstemmed Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
title_sort Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve, Bain
author Steve, Bain
author2 Christopher Sorli
Shin-ichi Harashima
George M Tsoukas
Jeffrey Unger
Julie Derving Karsbøl
Thomas Hansen
Steve Bain
format Journal article
container_title The Lancet Diabetes & Endocrinology
container_volume 5
container_issue 4
container_start_page 251
publishDate 2017
institution Swansea University
issn 2213-8587
doi_str_mv 10.1016/s2213-8587(17)30013-x
publisher Elsevier BV
college_str Swansea University Medical School
hierarchytype
hierarchy_top_id swanseauniversitymedicalschool
hierarchy_top_title Swansea University Medical School
hierarchy_parent_id swanseauniversitymedicalschool
hierarchy_parent_title Swansea University Medical School
department_str Medicine{{{_:::_}}}Swansea University Medical School{{{_:::_}}}Medicine
document_store_str 1
active_str 0
published_date 2017-04-01T03:47:32Z
_version_ 1711840220754739200
score 10.823361